Across TCGA pan-cancer cohorts, RPS6KL1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS6KL1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RPS6KL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS6KL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and COAD are the cancer types where RPS6KL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	III,IV	0.074	0.574	<.001	24	view →
UCEC	DFS	Median	All	0.962	0.613	.010	8	view →
COAD	DFS	Median	All	0.533	0.786	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPS6KL1 tumor-vs-normal RNA expression · all RPS6KL1 data types